Jie Jin

5PUBLICATIONS
19CO-AUTHORS
Haematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.

Huiqiang Huang, Rong Tao, Siguo Hao

|Oct 27, 2022
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).

Hongmei Jing, Li Yang, Junyuan Qi

|Oct 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing

|Sep 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Stephen Opat, Alessandra Tedeschi, Kim Linton

|Jul 13, 2021
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.

Gang An, Daobin Zhou, Shu Cheng

Pageof 1

Frequent Collaborators

1 joint publications

Jianfeng Zhou

1 joint publications

Yiling Yu

1 joint publications

Stephen Opat

1 joint publications

Pamela McKay